Skip to content
Explore cutting-edge articles on tech innovations, digital …

Giving Pluripotent Cells During Pregnancy to Infants with Spina Bifida Boosts Life Outcomes, Trial Finds

A groundbreaking clinical study has found that providing pluripotent cells to developing infants affected by spina bifida during corrective surgery can be a "significant breakthrough" in treating birth defects.

Trial Details and Safety

The research conducted in the United States examined six fetuses with the 'open' form of spina bifida. Surgeons applied placenta-derived mesenchymal stem cells to the surface of the baby's spinal cord during the repair procedure.

Significantly, the cell therapy proved to be secure. Researchers confirmed that the therapy did not induce neoplasms, hinder surgical recovery, or prevent the reversal of related neurological issues.

Promising Outcomes

Imaging conducted after delivery showed a successful correction of brainstem displacement in every participant. This neurological improvement is a key indicator for better mobility and function.

"In the event it allows more children capable of walking who previously could not, then it would become the conventional approach," commented the principal investigator. "The outcomes appear super exciting and open the door to numerous possible new treatments."

Long-Term Prospects and Optimism

Experts not involved in the trial have suggested that further confirmation of these apparent benefits could herald a "fresh chapter" in fetal surgery. The possibility of ameliorating neurological damage present before birth is considered a paradigm-shifting aim.

Particularly welcome would be improvements in bladder and bowel function, which are frequent complications for individuals living with this defect.

Looking Ahead

Despite this being a first-in-human effort was small in scale, its confirmed tolerability and hopeful trends offer a robust platform for broader investigative efforts. The integration of stem cell therapy with proven prenatal surgical methods holds considerable promise for changing life trajectories for infants diagnosed prenatally with myelomeningocele.

The writer

Reginald Ingram

A tech journalist and digital strategist with over a decade of experience covering emerging technologies and their impact on business.

Smart Blog UK

Type to search articles.